Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1996 • 809 citations

Tables of the number of patients required in clinical trials using the logrank test

1982 • 694 citations

Bayesian Approaches to Randomized Trials

1994 • 689 citations

The randomization and stratification of patients to clinical trials

1974 • 595 citations

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients

1998 • 565 citations

Gastric cancer treatment guidelines in Japan

2002 • 561 citations

Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials.

1993 • 560 citations

Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer

2000 • 437 citations

Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials

1999 • 416 citations

Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials

2000 • 362 citations

Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: The effect of undertreatment

2002 • 209 citations

Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer

2004 • 199 citations

Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses.

2002 • 198 citations

Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial

1999 • 166 citations

Randomized Trial of Adjuvant Chemotherapy With Mitomycin, Fluorouracil, and Cytosine Arabinoside Followed by Oral Fluorouracil in Serosa-Negative Gastric Cancer: Japan Clinical Oncology Group 9206–1

2003 • 163 citations

Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and G.E. junction. Results of intergroup study INT-0116 (SWOG 9008)

2001 • 139 citations

Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients

1993 • 110 citations

Preoperative assessment of lymph node metastases in patients with gastric cancer: evaluation of the Maruyama computer program

1992 • 103 citations

De Gramont Schedule is a Very Low Toxic and Effective Regimen in Low Performance Status Patients Affected by Metastatic Gastric Cancer: Preliminary Report

2002 • 68 citations

Clinical implications of dihydropyrimidine dehydrogenase inhibition.

1999 • 66 citations

Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer

2004 • 42 citations

Comparison of the molecular genetics ofc-erb-B2 and p53 expression in stomach cancer in Britain and Japan

1995 • 32 citations

Multimodality Therapy for Gastric Cancer

1999 • 27 citations

Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients

2007 • 23 citations

Adjuvant chemotherapy with uracil-tegafur (UFT) for serosa negative advanced gastric cancer: Results of a randomized trial by national surgical adjuvant study of gastric cancer

2005 • 18 citations

Meta-Analysis of Adjuvant Chemotherapy Trials for Gastric Cancer at the Cancer Institute Hospital, Tokyo

1999 • 6 citations

Cited By (0)

No citing papers found in database